Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 16 min 27 sec ago

Stereotaxis Submits 510(k) Application to FDA for Vdrive(TM) with V-Loop(TM) System

Tue, 04/01/2014 - 12:09
Announces First Vdrive Duo System Installation in North America ST. LOUIS, April 1, 2014 -- (Healthcare Sales & Marketing Network) -- Stereotaxis, Inc. (STXS) announced today that it has submitted a 510(k) Premarket Notification with the Food and Drug A...
Devices, Cardiology, Interventional, FDA
Stereotaxis, Vdrive, Robotic Navigation, V-Loop

Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer

Tue, 04/01/2014 - 12:02
SAN FRANCISCO, April 1, 2014 -- (Healthcare Sales & Marketing Network) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation...
Biopharmaceuticals, Diagnostics, Personnel
Amarantus Bioscience Holdings, Eltoprazine, LymPro Test, PhenoGuard, NuroPro

Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality

Tue, 04/01/2014 - 11:55
Immunotherapy and Vaccine Leader Also Promotes Three Executives in Legal, Clinical and Investor Relations BLUE BELL, Pa., April 1, 2014 -- (Healthcare Sales & Marketing Network) -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced the appoin...
Biopharmaceuticals, Oncology, Personnel
Inovio Pharmaceuticals, SynCon, vaccine, cancer vaccine

Johnson and Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics

Mon, 03/31/2014 - 13:09
NEW BRUNSWICK, N.J., March 31, 2014 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson (JNJ) today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Or...
Diagnostics, Mergers & Acquisitions
Johnson & Johnson, The Carlyle Group, Ortho-Clinical Diagnostics

Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion

Mon, 03/31/2014 - 13:01
First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J., March 31, 2014 -- (Healthcare Sales & Marketing Network) --...
Biopharmaceuticals, Cardiology
Daiichi Sankyo, ENSURE-AF, edoxaban, factor Xa-inhibitor

Eisai Assigns Its Worldwide Exclusive License for DACOGEN(R) to Otsuka

Mon, 03/31/2014 - 12:52
WOODCLIFF LAKE, N.J., March 31, 2014 -- (Healthcare Sales & Marketing Network) -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine)...
Biopharmaceuticals, Licensing
Eisai, Otsuka Pharmaceutical, DACOGEN, decitabine

New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer

Mon, 03/31/2014 - 12:47
The multidisciplinary Oncology Partnership and Education Network (OPEN) aims to improve patient outcomes in oncology, with initial focus on metastatic colorectal cancer (mCRC) OPEN aims to raise public awareness and understanding of the importance of bi...
Biopharmaceuticals, Oncology
Merck Serono, Oncology Partnership and Education Network, mCRC

Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)

Fri, 03/28/2014 - 15:40
Barrett S. McGrath Named as Chief Commercial Officer CORAL GABLES, Fla., March 28, 2014 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceutical Partners, Inc. (CPRX), a specialty pharmaceutical company focused on developing safe and effecti...
Biopharmaceuticals, Neurology, Personnel
Catalyst Pharmaceutical, Firdapse, Lambert-Eaton Myasthenic Syndrome

aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer

Fri, 03/28/2014 - 12:44
Clinical Leader Brings Strong Drug Development Background and Expertise SAN DIEGO, March 28, 2014 -- (Healthcare Sales & Marketing Network) -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today that David M. Wein...
Biopharmaceuticals, Personnel
aTyr Pharma, Physiocrine

NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

Fri, 03/28/2014 - 12:33
Carl Adams Promoted to Chief Financial Officer and Craig Rostamian Joins as Vice President of Finance LOS ANGELES, March 28, 2014 -- (Healthcare Sales & Marketing Network) -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focus...
Devices, Neurology, Personnel
NeuroSigma, Monarch eTNS System

Real-Time Dose Monitoring from Toshiba Makes Cardiac Interventions Safer

Fri, 03/28/2014 - 12:26
Dose Tracking System Optimizes Dose Management Like Never Before WASHINGTON--(Healthcare Sales & Marketing Network)--With the unmatched flexibility to measure radiation peak skin dose in real time, Toshiba America Medical Systems, Inc.’s Dose Tracking S...
Devices, Interventional, Radiology, Cardiology
Toshiba America Medical Systems, Dose Tracking System, Infinix-i

CryoLife Acquires Distribution Rights and Purchase Option for ProCol(R) Vascular Bioprosthesis for Hemodialysis Access

Thu, 03/27/2014 - 16:47
Provides access for dialysis patients; complementary to HeRO® Graft ATLANTA, March 27, 2014 -- (Healthcare Sales & Marketing Network) -- CryoLife, Inc. (CRY), a leading medical device and tissue processing company focused on cardiac and vascular su...
Devices, Distribution
CryoLife, ProCol, Vascular Bioprosthesis, dialysis

Accuray Incorporated's CyberKnife(R) M6(TM) System Receives Shonin Approval

Thu, 03/27/2014 - 16:43
Latest CyberKnife technology now available in Japan SUNNYVALE, Calif., March 27, 2014 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today it received Shonin approval from the Japanese Ministry of Health, Labor and W...
Devices, Oncology, Regulatory
Accuray, CyberKnife, CyberKnife M6, radiosurgery, radiotherapy

Nora Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton

Thu, 03/27/2014 - 16:41
PALO ALTO, Calif., March 27, 2014 -- (Healthcare Sales & Marketing Network) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced that Dennis M. Fenton, Ph.D. has ...
Biopharmaceuticals, Personnel
Nora Therapeutics, in vitro fertilization

Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its Board of Directors

Thu, 03/27/2014 - 16:38
PETALUMA, Calif., March 27, 2014 -- (Healthcare Sales & Marketing Network) -- Oculus Innovative Sciences, Inc. (OCLS), today announced the appointment of Sharon Barbari to its board of directors, effective March 26, 2014. "We are delighted to have ...
Devices, Wound Care, Personnel
Oculus Innovative Sciences

Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies

Thu, 03/27/2014 - 16:32
Independent Companies Will Focus On Biopharmaceuticals And Medical Products Company Plans Tax-Free Distribution Of New Publicly Traded Stock In New Biopharmaceuticals Business DEERFIELD, Ill.--(Healthcare Sales & Marketing Network)--Baxter Internat...
Biopharmaceuticals, Devices, Personnel
Baxter

Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007

Thu, 03/27/2014 - 11:41
WHITEHOUSE STATION, N.J.--(Healthcare Sales & Marketing Network)--Merck (MRK), known as MSD outside the United States and Canada, today announced the appointment of Robert M. Davis, 47, as executive vice president and chief financial officer, effective Apr...
Biopharmaceuticals, Personnel
Merck

Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients

Thu, 03/27/2014 - 11:31
The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation Study aims to recruit 946 patients across 17 European countries DARMSTADT, Germany, March 27, 2014 -- (Healthcare Sales & Marketing Networ...
Biopharmaceuticals
Merck KGaA, ESPART study, Pergoveris, GONAL-f, follicle stimulating hormone

Cesca Therapeutics Submits pre-IDE Information Package to FDA for Surgwerks(TM) CLI therapy System

Wed, 03/26/2014 - 15:10
Company to Meet FDA and Receive Feedback During Summer 2014 RANCHO CORDOVA, Calif., March 26, 2014 -- (Healthcare Sales & Marketing Network) -- Cesca Therapeutics, Inc. (KOOL), an autologous cell based regenerative medicine company, announced it has sub...
Regenerative Medicine, FDA
Cesca Therapeutics, SurgWerks, critical limb ischemia, stem cell

Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller Chief Operating Officer

Wed, 03/26/2014 - 15:04
HOUSTON--(Healthcare Sales & Marketing Network)--Bio-Path Holdings, Inc., (BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr. Ulrich W. Mueller has joined the Compa...
Biopharmaceuticals, Drug Delivery, Oncology, Personnel
Bio-Path Holdings, liposomal delivery, nucleic acid

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong